T-cell Immunoglobulin Mucin Family Member 3 Uses, Dosage, Side Effects and more
T-cell Immunoglobulin Mucin Family Member 3 is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
| Trade Name | T-cell Immunoglobulin Mucin Family Member 3 |
| Generic | Sabatolimab |
| Sabatolimab Other Names | Anti-tim-3 monoclonal antibody mbg453, Anti-tim3 checkpoint inhibitor mbg453, Immunoglobulin g4 (226-proline,de-c-terminal-lysine), anti-(human hepatitis virus a cellular receptor 2) (human-mus musculus monoclonal clone nvs260714 .gamma.4-chain), disulfide with human-mus musculus monoclonal clone nvs260714 .kappa.-chain, dimer, Immunoglobulin g4-kappa, anti-(homo sapiens havcr2 (hepatitis a virus cellular receptor 2, t-cell immunoglobulin mucin family member 3, tim-3, tim3, timd3, cd366)), humanized monoclonal antibody, Sabatolimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
